EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Feasibility of risk assessment for breast cancer molecular subtypes

Anne Marie McCarthy, Sarah Ehsan, Kevin S Hughes, Constance D Lehman, Emily F Conant, Despina Kontos, Katrina Armstrong, Jinbo Chen

Breast Cancer Research and Treatment · 2024-11 · 208 (1) · 103-110

DOI: 10.1007/s10549-024-07404-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 25.06.2024. Verfasst von Anne Marie McCarthy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Blockley Hall, Room 833, 423 Guardian Drive, Philadelphia, PA,…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Receptors, Progesterone, Receptors, Estrogen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Cancer Society, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Few breast cancer risk assessment models account for the risk profiles of different tumor subtypes. This study evaluated whether a subtype-specific approach improves discrimination.

Methods

Among 3389 women who had a screening mammogram and were later diagnosed with invasive breast cancer we performed multinomial logistic regression with tumor subtype as the outcome and known breast cancer risk factors as predictors. Tumor subtypes were defined by expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) based on immunohistochemistry. Discrimination was assessed with the area under the receiver operating curve (AUC). Absolute risk of each subtype was estimated by proportioning Gail absolute risk estimates by the predicted probabilities for each subtype. We then compared risk factor distributions for women in the highest deciles of risk for each subtype.

Results

There were 3,073 ER/PR+ HER2 − , 340 ER/PR +HER2 + , 126 ER/PR−ER2+, and 300 triple-negative breast cancers (TNBC). Discrimination differed by subtype; ER/PR−HER2+ (AUC: 0.64, 95% CI 0.59, 0.69) and TNBC (AUC: 0.64, 95% CI 0.61, 0.68) had better discrimination than ER/PR+HER2+ (AUC: 0.61, 95% CI 0.58, 0.64). Compared to other subtypes, patients at high absolute risk of TNBC were younger, mostly Black, had no family history of breast cancer, and higher BMI. Those at high absolute risk of HER2+ cancers were younger and had lower BMI.

Conclusion

Our study provides proof of concept that stratifying risk prediction for breast cancer subtypes may enable identification of patients with unique profiles conferring increased risk for tumor subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenBiomarkers, TumorHumansFemaleRisk AssessmentMiddle AgedAgedAdultRisk FactorsROC CurveFeasibility StudiesImmunohistochemistryTriple Negative Breast NeoplasmsMammography

Stichwörter der Autor:innen

Breast cancerRisk assessmentRisk prediction modelTriple-negative breast cancerTumor subtypes

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Blockley Hall, Room 833, 423 Guardian Drive, Philadelphia, PA, 19104, USA. annemcc@pennmedicine.upenn.edu.
  • Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Blockley Hall, Room 833, 423 Guardian Drive, Philadelphia, PA, 19104, USA.
  • Department of Surgery, Medical University of South Carolina, Charleston, SC, 29425, USA.
  • Massachusetts General Hospital, Boston, MA, USA.
  • Department of Radiology, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Columbia University Irving Medical Center, New York, NY, USA.

Förderung

  • NCI NIH HHS
  • American Cancer Society
  • NCATS NIH HHS

Zitieren

APA

McCarthy, A. M., Ehsan, S., Hughes, K. S., Lehman, C. D., Conant, E. F., Kontos, D., Armstrong, K., & Chen, J. (2024). Feasibility of risk assessment for breast cancer molecular subtypes. Breast Cancer Research and Treatment, 208(1), 103-110. https://doi.org/10.1007/s10549-024-07404-9

Vancouver

McCarthy AM, Ehsan S, Hughes KS, Lehman CD, Conant EF, Kontos D, et al. Feasibility of risk assessment for breast cancer molecular subtypes. Breast Cancer Research and Treatment. 2024;208(1):103-110. doi:10.1007/s10549-024-07404-9

BibTeX
@article{McCarthy2024,
  author = {McCarthy, Anne Marie and Ehsan, Sarah and Hughes, Kevin S and Lehman, Constance D and Conant, Emily F and Kontos, Despina and Armstrong, Katrina and Chen, Jinbo},
  title = {Feasibility of risk assessment for breast cancer molecular subtypes},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  volume = {208},
  number = {1},
  pages = {103--110},
  doi = {10.1007/s10549-024-07404-9}
}
Kostenlos starten →